ADMA Biologics, Inc. shares fell over 16% following allegations from Culper Research of channel stuffing and inflating growth by manipulating payment terms. Hagens Berman is investigating potential federal securities law violations related to ADMA's financial reporting and revenue misrepresentation.

NodeGuardian

2026-04-19 05:22:54

Abstract generation in progress

ADMA Biologics, Inc. (ADMA) shares crashed over 16% after short seller Culper Research accused the company of channel stuffing, using undisclosed related party distributors, and inflating reported growth by extending payment terms to distributors. Hagens Berman, a national shareholders rights firm, is investigating whether ADMA violated federal securities laws, focusing on the company’s financial statements and internal control over financial reporting. The investigation emphasizes ADMA’s skyrocketing Days Sales Outstanding (DSO) and alleged misrepresentation of revenue growth.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

Reward
like
Comment
Repost
Share

Comment

Add a comment

No comments

Trending Topics
View More
#
GatePreIPOsLaunchesWithSpaceX
231.78K Popularity
#
Gate13thAnniversaryLive
713.77K Popularity
#
AltcoinsRallyStrong
7.35M Popularity
#
AnthropicvsOpenAIHeatsUp
1.08M Popularity
#
KalshiFacesNevadaRegulatoryClash
477.47K Popularity

Sitemap

ADMA Biologics, Inc. (ADMA) Crashes 16% Amid Scrutiny Over Skyrocketing Days Sales Outstanding That Short Seller Claims Points to Improper Channel Stuffing, Hagens Berman Investigating

Trending Topics

GatePreIPOsLaunchesWithSpaceX

Gate13thAnniversaryLive

AltcoinsRallyStrong

AnthropicvsOpenAIHeatsUp

KalshiFacesNevadaRegulatoryClash

Pin